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Congenital muscular dystrophy type 1A (MDC1A) is an autosomal recessive disorder characterized 
by hypotonia, elevated serum creatine kinase level, delayed motor milestones, white matter changes 
observed by brain magnetic resonance imaging, and normal intelligence. A mutation in the laminin α2 
(LAMA2) gene, located at 6q22-23, is a genetic cause of MDC1A. Patients have merosin (laminin α2)-
deficient skeletal muscles. However, the degree of merosin expression ranges from total absence to 
partial reduction. Patients with residual merosin expression have more variable and milder phenotypes 
than those with absolute merosin deficiency. We observed a Korean girl with MDC1A with residual 
merosin expression. Clinical presentation of this patient was typical except for late onset of the disease 
and external capsule involvement. Immunohistochemical staining of muscle fibers including merosin, is 
important to evaluate patients with hypotonia, delayed motor development, and abnormal white matter 
changes.
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Introduction
Congenital muscular dystrophy type 1A (MDC1A) was first described in 1994 as a variant 
form of classic congenital muscular dystrophy (CMD)1). MDC1A is an autosomal recessive 
disorder, and patients show absent merosin (laminin α2) on skeletal muscle biopsy. A 
mutation in the laminin α2 (LAMA2) gene, located on 6q22-23, was later found to be a 
genetic cause of MDC1A2). Most patients with MDC1A show absent merosin in muscle 
immunohistochemistry studies, however, there have been some reports of cases of 
MDC1A with residual merosin expression3-5). MDC1A is very rare in Asian countries. 
Comparing with  studies conducted in western countries2,3), only a few cases without 
merosin expression have been reported in the Asian population6-8). Here, we describe a 
patient with MDC1A and residual merosin expression.
Case report
The patient was born at 38 weeks of gestation with a birth weight of 3,500 gm. There was no 
history of decreased fetal movement and asphyxia at birth. She was a second child, with one 
4-year-old brother with no medical problems. There was no history of parental consanguinity. 
She was healthy at birth, but her parents noticed that she had a delayed motor milestone 
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at the age of 4 months as indicated by her inability to fully control 
her head. She was brought to Severance Children’s Hospital for the 
first time at the age of 4 months and was hypotonic at that time. 
The traction test showed headlag, and the suspension test showed 
inverted U sign. Deep tendon reflexes were weakly preserved. She 
was fully examined for muscular disease at the age of 6 months, 
at which time she could not yet control her head. However the 
Bayley Scales of Infant Development for language and cognitive 
development were normal. Her serum creatine kinase (CK) level 
was elevated to 2,184 IU/L (0–50 norm) and her serum aldolase 
level was also high at 31.6 sigma U/mL (0–7.6 norm). In a nerve 
conduction study, both sensory and motor conduction were 
shown to be normal. Electrocardiography and echocardiography 
showed no abnormalities. Brain magnetic resonance imaging 
(MRI) performed at the age of 6 months showed excessive T2 
hyper-intensity at the peritrigone and external capsule (Fig. 1). 
Repeated brain MRI at the age of 8 months showed progression 
of dysmyelination. We performed a muscle biopsy in the left 
vastus lateralis muscle. Hematoxylin and eosin staining showed 
marked muscle fiber size variation, increased endomysial fib-
rosis, many endomysial inflammatory cell infiltrations, and 
many necrotic and regenerative muscle fibers (Fig. 2). Mo dified 
Gomori trichrome staining did not show ragged red fibers, 
nemaline bodies, or rimmed vacuoles. Nicotinamide adenine 
dinucleotide-tetrazolium reductase staining showed disor ganized 
inter-myofibrillar networks. These findings suggest muscular 
dystrophic changes. Immunohistochemical staining was performed 
using antibodies against the C-terminal of dystrophin, rod domain of 
dystrophin, N-terminal of dystrophin, α-sarcoglycan, β-sarcoglycan, 
γ-sarcoglycan, δ-sarcoglycan, dysferlin, α-dystroglycan, caveolin 
3, and laminin α2. Staining against laminin α2 was partially 
decreased, while the others were normally expressed (Fig. 3). 
To confirm mutation in the LAMA2 gene, we performed direct 
sequencing of exons 14, 25, 26, and 27, all of which are known 
as common sites of mutation. However, no point mutations were 
identified.
A B 
Fig. 1. Axial T2-weighted brain magnetic resonance images of the patient at 6 months of age shows 
high signal intensity in the white matter of the peritrigone and external capsule (A); slight progression of 
dysmyelination can be seen 2 months later (B).
A B 
Fig. 2. Hematoxylin and eosin staining shows marked muscle fiber size variation, increased endomysial 
fibrosis, numerous endomysial inflammatory cell infiltrations, and increased necrotic and regenerative 
muscle fibers (A, ×200; B, ×400).
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Discussion
Typical clinical features of MDC1A or merosin deficient con-
genital muscular dystrophy include severe floppiness at birth, 
elevated serum CK, delayed motor milestones, white matter changes 
as seen on brain MRI, and normal intelligence2). However, merosin- 
positive CMD generally presents with less severe clinical features 
and without any abnormalities on brain MRI2,5). Initially, MDC1A 
was thought to be a homogenous disease; however, case reports 
of atypical phenotypes and some cases showing only partially 
reduced merosin expression contributed to classifying the disease 
as a heterogeneous group3,5). There have been MDC1A patients 
who show late-onset weakness, mental retardation, seizures, 
subclinical cardiac involvement, or neuronal migration defects9). 
In particular, cases with residual merosin expression have more 
variable phenotypes than cases with absolute merosin deficiency. 
According to previous reports, patients with residual merosin 
tend to have milder phenotypes3,5). With regards to ambulation, a 
previous study showed that eight out of 12 patients with residual 
merosin achieved independent ambulation, whereas, out of four 
patients with absent merosin, none could walk independently5). 
Another study presented similar results: five out of 13 patients 
with residual merosin and two out of 33 patients with absent 
merosin could walk independently3). 
In our case, the onset of symptoms was 4 months after birth, 
rather than during the neonatal period. Usually, merosin deficient 
patients present with symptoms within 7 days of birth, while 
patients with residual merosin have a later onset of symptoms. 
The other symptoms of this patient, such as hypotonia, normal 
intelligence, elevated serum CK, and the absence of seizures, are 
typical presentations of MDC1A patients. At present, she is 14 
months old, and can sit without support but cannot get into a 
sitting position. We estimate that she has about a 50% probability of 
walking independently later in her life. 
Brain MRI of this patient showed typical hyperintensity in the 
T2-weighted image. However, the patient’s site of lesion is in 
the external capsule, which is an unusual area for this disease. A 
study of 25 Brazilian patients with MDC1A reported that bilateral 
white matter involvement in the parietal, frontal, and temporal 
regions was frequent, and brain stem, cerebellum, and internal and 
external capsules were also affected in a minority of cases10). 
However, there were no correlations with sites of white matter 
abnormalities and clinical status or merosin status.
To confirm mutation of the LAMA2 gene, we sequenced exons 
14, 25, 26, and 27. This technique, while able to screen for point 
mutations in above 4 exons, is limited in its ability to detect large 
deletions or insertions or point mutations in the other sites. We 
did not further evaluate other possible mutations in the LAMA2 
gene because of her parents’ refusal. According to a previous 
report, a majority of mutations in the residual merosin group 
are splice site mutations, and frameshift mutations are less fre-
quent3). This patient may have mutations in her LAMA2 gene, 
although we could not confirm the specific mutations because of 
incomplete study.
MDC1A is very rare in Asia, and the cases reported thus far are 
typically those without merosin, and have mostly been severe 
forms of MDC1A. In our study, the patient showed a typical 
phenotype of MDC1A, including features such as hypotonia, 
elevated serum CK, delayed motor development, and T2 hyperin-
tensity on brain MRI. However, immunohistochemical staining 
of the muscle fibers showed partially decreased merosin levels 
and some atypical findings, such as a somewhat later age of dis-
ease onset and involvement of the external capsule. From our 
experience, performing immunohistochemical staining to assay 
the extent of merosin expression is an important procedure, and 
may be helpful in predicting the clinical course of the disease.
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Fig. 3. Immunohistochemical staining of the patient’s muscle fiber demonstrates partially decreased laminin α2 
expression (A, ×400) comparing with normal expression of dystrophin (B, ×400) and α-dystroglycan (C, ×400).
http://dx.doi.org/10.3345/kjp.2014.57.3.149
Kim HJ, et al. • MDC1A with residual merosin expression
152
References
 1.  Tome FM, Evangelista T, Leclerc A, Sunada Y, Manole E, Estournet 
B, et al. Congenital muscular dystrophy with merosin deficiency. C 
R Acad Sci III 1994;317:351-7.
 2.  Pegoraro E, Marks H, Garcia CA, Crawford T, Mancias P, Connolly 
AM, et al. Laminin alpha2 muscular dystrophy: genotype/phenotype 
studies of 22 patients. Neurology 1998;51:101-10.
 3.  Geranmayeh F, Clement E, Feng LH, Sewry C, Pagan J, Mein R, 
et al. Genotype-phenotype correlation in a large population of 
muscular dystrophy patients with LAMA2 mutations. Neuromuscul 
Disord 2010;20:241-50.
 4.  Philpot J, Sewry C, Pennock J, Dubowitz V. Clinical phenotype in 
congenital muscular dystrophy: correlation with expression of 
merosin in skeletal muscle. Neuromuscul Disord 1995;5:301-5.
 5.  Morandi L, Di Blasi C, Farina L, Sorokin L, Uziel G, Azan G, et al. 
Clinical correlations in 16 patients with total or partial laminin 
alpha2 deficiency characterized using antibodies against 2 frag-
ments of the protein. Arch Neurol 1999;56:209-15.
 6.  Chae JH, Lee JS, Hwang H, Kim KJ, Hwang YS, Park JD, et al. 
Merosin-deficient congenital muscular dystrophy in Korea. Brain 
Dev 2009;31:341-6.
 7.  Yuan J, Takashima H, Higuchi I, Arimura K, Li N, Zhao Z, et al. 
Genetically confirmed patients with merosin-deficient congenital 
muscular dystrophy in China. Neuropediatrics 2008;39:264-7.
 8.  Fujii Y, Sugiura C, Fukuda C, Maegaki Y, Ohno K. Sequential neu-
roradiological and neurophysiological studies in a Japanese girl 
with merosin-deficient congenital muscular dystrophy. Brain Dev 
2011;33:140-4.
 9.  Jones KJ, Morgan G, Johnston H, Tobias V, Ouvrier RA, Wilkinson 
I, et al. The expanding phenotype of laminin alpha2 chain (merosin) 
abnormalities: case series and review. J Med Genet 2001;38:649-
57.
 10.  Leite CC, Lucato LT, Martin MG, Ferreira LG, Resende MB, Carvalho 
MS, et al. Merosin-deficient congenital muscular dystrophy (CMD): 
a study of 25 Brazilian patients using MRI. Pediatr Radiol 2005;35: 
572-9.
